BRL Medicine Non viral Targeted Integration PD1-CAR-T Therapy for Lupus Erythematosus Approved by China IND

Molecular Cell article! BRL Medicine has developed a new gene editing tool with high activity and smaller size

It's been more than 4 years since the first patient with β-thalassemia was cured with BRL Medicine's gene therapy

BRL Medicine's UCAR-T results are published in Cell, highlighting a significant breakthrough in autoimmune disease

BRL Medicine's non-viral PD1-CAR-T product "BRL-201" were presented at the 2024 ASCO conference

The research results of BRL-101 will be presented at the 27th ASGCT Annual Meeting